Clinical Efficacy and Outcomes of Remibrutinib (LOU064) in Patients with Chronic Spontaneous Urticaria Inadequately Controlled with H1-Antihistamines: Findings from a Phase IIb Study

[摘要] As part of the 31 st European Academy of Dermatology and Venereology (EADV) Annual Congress held in Milan, Italy, and online, 7 th –10 th September 2022, five poster presentations outlined results from the Phase IIb study of remibrutinib (LOU064) in patients with chronic spontaneous urticaria inadequately controlled with H1-antihistamines. These posters presented data on quality of life, the need for antihistamine rescue medication to address symptoms, the time to complete urticaria control, and the safety profile of remibrutinib. The findings were outlined in these poster presentations and are summarised here.

[学科分类] 公共、环境与职业健康